A familiar signal, changed to last longer
Semaglutide, the ingredient in Wegovy and Ozempic, is an altered copy of GLP-1. That's a gut hormone involved in appetite and blood sugar. The changes help it stay in the body longer than the natural hormone.
That explains the starting idea. To find out whether it helped people, researchers had to test it. The weight trial is a useful place to begin.
The weight difference was substantial
In STEP 1, a trial of adults with obesity or with overweight plus a weight-related condition, participants had no diabetes. Average weight fell by about 15% with semaglutide injections over 68 weeks. The placebo group lost about 2%. Both groups had lifestyle support, which belongs in the story too.
An average isn't a forecast for the person reading this. It shows that the groups differed, while leaving room for different individual experiences. Another trial asked a question that went beyond the scales.
The heart finding needs its context
A heart-outcomes trial studied adults aged 45 or older with established cardiovascular disease and overweight or obesity, without diabetes. Cardiovascular death, nonfatal heart attack or nonfatal stroke, counted together, happened less often with semaglutide injections than with placebo.
That's a meaningful health finding. It doesn't establish the same protection for everyone, and it isn't evidence that semaglutide slows aging. The people enrolled help define what the answer means.
Taken together, these trials give us more than a plausible idea. They still leave an individual care decision, including the risks, to work through.
The awkward effects are part of the answer
Nausea, vomiting, diarrhea and constipation are common concerns in the safety evidence. The Wegovy label also warns about gallbladder problems and pancreatitis, inflammation of the pancreas. A benefit doesn't make those experiences disappear.
The label's boxed warning concerns thyroid tumors seen in rodents; the risk in people is unknown. It rules out use with a personal or family history of medullary thyroid cancer, or with MEN 2, an inherited condition. Pregnancy plans, severe stomach-emptying problems and other medicines also matter to a review.
Compounded semaglutide is not FDA-approved. The FDA's explanation of compounding helps separate an ingredient's name from approval of a finished product. These pages give no personal dosing plan.
Stepping back, semaglutide shows what substantial human evidence can look like, with limits still attached. The MOTS-c page starts much earlier in that process. Sharing the word peptide doesn't put them at the same point.